A clinically translatable mouse model for chemotherapy-related fatigue

Comparative Medicine

Volumn 63, Issue 6, 2013, Pages 491-497

  Zombeck, Jonathan A ^a   Fey, Edward G ^a   Lyng, Gregory D ^a   Sonis, Stephen T ^a  

^a Biomodels   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; MODAFINIL; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER FATIGUE; CHEMOTHERAPY INDUCED FATIGUE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DYING; ERYTHROCYTE COUNT; FEMALE; MOTOR COORDINATION; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OPEN FIELD TEST; QUALITATIVE ANALYSIS; ROTAROD TEST; RUNNING; TREADMILL; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BEHAVIOR, ANIMAL; BENZHYDRYL COMPOUNDS; DISEASE MODELS, ANIMAL; DOXORUBICIN; FATIGUE; FEMALE; MICE; MICE, INBRED ICR;

EID: 84892583147     PISSN: 15320820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Alexander S, Minton O, Andrews P, Stone P. 2009. A comparison of the characteristics of disease-free breast cancer survivors with or without cancer-related fatigue syndrome. Eur J Cancer 45:384-392.
2. Ancoli-Israel S, Liu L, Marler MR, Parker BA, Jones V, Sadler GR, Dimsdale J, Cohen-Zion M, Fiorentino L. 2006. Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer. Support Care Cancer 14:201-209.
3. Andrykowski MA, Donovan KA, Jacobsen PB. 2009. Magnitude and correlates of response shift in fatigue ratings in women undergoing adjuvant therapy for breast cancer. J Pain Symptom Manage 37:341-351.
4. Berger AM. 1998. Patterns of fatigue and activity and rest during adjuvant breast cancer chemotherapy. Oncol Nurs Forum 25:51-62.
5. Berglund G, Bolund C, Fornander T, Rutqvist LE, Sjoden PO. 1991. Late effects of adjuvant chemotherapy and postoperative radiotherapy on quality of life among breast cancer patients. Eur J Cancer 27:1075-1081.
6. Blackhall L, Petroni G, Shu J, Baum L, Farace E. 2009. A pilot study evaluating the safety and efficacy of modafinal for cancer-related fatigue. J Palliat Med 12:433-439.
7. Bower JE, Ganz PA, Aziz N. 2005. Altered cortisol response to psychologic stress in breast cancer survivors with persistent fatigue. Psychosom Med 67:277-280.
8. Bower JE, Ganz PA, Desmond KA, Bernaards C, Rowland JH, Meyerowitz BE, Belin TR. 2006. Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer 106:751-758.
9. Broeckel JA, Jacobsen PB, Horton J, Balducci L, Lyman GH. 1998. Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol 16:1689-1696.
10. Bruera E, Valero V, Driver L, Shen L, Willey J, Zhang T, Palmer JL. 2006. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 24:2073-2078.
11. Butler JM Jr, Case LD, Atkins J, Frizzell B, Sanders G, Griffin P, Lesser G, McMullen K, McQuellon R, Naughton M, Rapp S, Stieber V, Shaw EG. 2007. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys 69:1496-1501.
12. Campos MP, Hassan BJ, Riechelmann R, Del Giglio A. 2011. Cancer-related fatigue: a practical review. Ann Oncol 22:1273-1279.
13. Cella D. 1997. The functional assessment of cancer therapy-anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34:13-19.
14. Cella D, Peterman A, Passik S, Jacobsen P, Breitbart W. 1998. Progress toward guidelines for the management of fatigue. Oncology (Williston Park) 12:369-377.
15. Chen Y, Jungsuwadee P, Vore M, Butterfield DA, St Clair DK. 2007. Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues. Mol Interv 7:147-156.
16. Clark PJ, Brzezinska WJ, Thomas MW, Ryzhenko NA, Toshkov SA, Rhodes JS. 2008. Intact neurogenesis is required for benefits of exercise on spatial memory but not motor performance or contextual fear conditioning in C57BL/6J mice. Neuroscience 155:1048-1058.
17. Clark PJ, Kohman RA, Miller DS, Bhattacharya TK, Brzezinska WJ, Rhodes JS. 2011. Genetic influences on exercise-induced adult hippocampal neurogenesis across 12 divergent mouse strains. Genes Brain Behav 10:345-353.
18. Cramp F, Daniel J. 2008. Exercise for the management of cancerrelated fatigue in adults. Cochrane Database Syst RevCD006145.
19. Crawley JN. 1985. Exploratory behavior models of anxiety in mice. Neurosci Biobehav Rev 9:37-44.
20. Curt GA. 2000. The impact of fatigue on patients with cancer: overview of FATIGUE 1 and 2. Oncologist 5 Suppl 2:9-12.
21. Dantzer R. 2009. Cytokine, sickness behavior, and depression. Immunol Allergy Clin North Am 29:247-264.
22. Deacon RM. 2009. Burrowing: a sensitive behavioural assay, tested in 5 species of laboratory rodents. Behav Brain Res 200:128-133.
23. Demetri GD, Kris M, Wade J, Degos L, Cella D. 1998. Quality-of-life benefit in chemotherapy patients treated with epoetin-α is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16:3412-3425.
24. Foltz C, Ullman-Cullere M. 1999. Guidelines for assessing the health and condition of mice. Lab Anim (NY) 28:28-32.
25. Fung FY, Li M, Breunis H, Timilshina N, Minden MD, Alibhai SM. 2013. Correlation between cytokine levels and changes in fatigue and quality of life in patients with acute myeloid leukemia. Leuk Res 37:274-279.
26. Galvao DA, Newton RU. 2005. Review of exercise intervention studies in cancer patients. J Clin Oncol 23:899-909.
27. Gilliam LA, Ferreira LF, Bruton JD, Moylan JS, Westerblad H, St Clair DK, Reid MB. 2009. Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle. J Appl Physiol 107:1935-1942.
28. Hanna A, Sledge G, Mayer ML, Hanna N, Einhorn L, Monahan P, Daggy J, Bhatia S. 2006. A phase II study of methylphenidate for the treatment of fatigue. Support Care Cancer 14:210-215.
29. Harrington ME. 2012. Neurobiological studies of fatigue. Prog Neurobiol 99:93-105.
30. Holzner B, Kemmler G, Greil R, Kopp M, Zeimet A, Raderer M, Hejna M, Zochbauer S, Krajnik G, Huber H, Fleischhacker WW, Sperner-Unterweger B. 2002. The impact of hemoglobin levels on fatigue and quality of life in cancer patients. Ann Oncol 13:965-973.
31. Hurny C, Bernhard J, Joss R, Schatzmann E, Cavalli F, Brunner K, Alberto P, Senn HJ, Metzger U. 1993. 'Fatigue and malaise' as a qualityof-life indicator in small-cell lung cancer patients. The Swiss Group for Clinical Cancer Research (SAKK). Support Care Cancer 1:316-320.
32. Hydock DS, Lien CY, Jensen BT, Schneider CM, Hayward R. 2011. Characterization of the effect of in vivo doxorubicin treatment on skeletal muscle function in the rat. Anticancer Res 31:2023-2028.
33. Innominato PF, Mormont MC, Rich TA, Waterhouse J, Levi FA, Bjarnason GA. 2009. Circadian disruption, fatigue, and anorexia clustering in advanced cancer patients: implications for innovative therapeutic approaches. Integr Cancer Ther 8:361-370.
34. Ishizuka T, Murakami M, Yamatodani A. 2008. Involvement of central histaminergic systems in modafinil-induced but not methylphenidate-induced increases in locomotor activity in rats. Eur J Pharmacol 578:209-215.
35. Jacobsen PB. 2004. Assessment of fatigue in cancer patients. J Natl Cancer Inst Monogr 2004:93-97.
36. Jacobsen PB, Donovan KA, Small BJ, Jim HS, Munster PN, Andrykowski MA. 2007. Fatigue after treatment for early stage breast cancer: a controlled comparison. Cancer 110:1851-1859.
37. Jean-Pierre P, Morrow GR, Roscoe JA, Heckler C, Mohile S, Janelsins M, Peppone L, Hemstad A, Esparaz BT, Hopkins JO. 2010. A phase III randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer 116:3513-3520.
38. Kangas M, Bovbjerg DH, Montgomery GH. 2008. Cancer-related fatigue: a systematic and metaanalytic review of nonpharmacological therapies for cancer patients. Psychol Bull 134:700-741.
39. Kirshner J, Hatch M, Hennessy DD, Fridman M, Tannous RE. 2004. Anemia in stage II and III breast cancer patients treated with adjuvant doxorubicin and cyclophosphamide chemotherapy. Oncologist 9:25-32.
40. Lin JS, Hou Y, Jouvet M. 1996. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci USA 93:14128-14133.
41. Lower EE, Fleishman S, Cooper A, Zeldis J, Faleck H, Yu Z, Manning D. 2009. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage 38:650-662.
42. Malik NM, Liu YL, Cole N, Sanger GJ, Andrews PL. 2007. Differential effects of dexamethasone, ondansetron and a tachykinin NK1 receptor antagonist (GR205171) on cisplatin-induced changes in behaviour, food intake, pica, and gastric function in rats. Eur J Pharmacol 555:164-173.
43. Malik NM, Moore GB, Smith G, Liu YL, Sanger GJ, Andrews PL. 2006. Behavioural and hypothalamic molecular effects of the anticancer agent cisplatin in the rat: a model of chemotherapy-related malaise? Pharmacol Biochem Behav 83:9-20
44. Mar Fan HG, Clemons M, Xu W, Chemerynsky I, Breunis H, Braganza S, Tannock IF. 2008. A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer 16:577-583.
45. Minton O, Stone P. 2009. A systematic review of the scales used for the measurement of cancer-related fatigue (CRF). Ann Oncol 20:17-25.
46. Moraska AR, Sood A, Dakhil SR, Sloan JA, Barton D, Atherton PJ, Suh JJ, Griffin PC, Johnson DB, Ali A, Silberstein PT, Duane SF, Loprinzi CL. 2010. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. J Clin Oncol 28:3673-3679.
47. Payne JK. 2011. Altered circadian rhythms and cancer-related fatigue outcomes. Integr Cancer Ther 10:221-233.
48. Pointon AV, Walker TM, Phillips KM, Luo J, Riley J, Zhang SD, Parry JD, Lyon JJ, Marczylo EL, Gant TW. 2010. Doxorubicin in vivo rapidly alters expression and translation of myocardial electron transport chain genes, leads to ATP loss and caspase 3 activation. PLoS ONE 5:e12733.
49. Ray MA, Trammell RA, Verhulst S, Ran S, Toth LA. 2011. Development of a mouse model for assessing fatigue during chemotherapy. Comp Med 61:119-130.
50. Redmond K. 1996. Advances in supportive care. Eur J Cancer Care (Engl) 5:1-7.
51. Rhodes JS, Garland T. 2003. Differential sensitivity to acute administration of Ritalin, apomorphine, SCH 23390, but not raclopride in mice selectively bred for hyperactive wheel-running behavior. Psychopharmacology (Berl) 167:242-250.
52. Richardson A, Ream E, Wilson-Barnett J. 1998. Fatigue in patients receiving chemotherapy: patterns of change. Cancer Nurs 21:17-30.
53. Roth AJ, Nelson C, Rosenfeld B, Scher H, Slovin S, Morris M, O'Shea N, Arauz G, Breitbart W. 2010. Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer 116:5102-5110.
54. Schubert C, Hong S, Natarajan L, Mills PJ, Dimsdale JE. 2007. The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun 21:413-427.
55. Silberfarb PM, Hauri PJ, Oxman TE, Schnurr P. 1993. Assessment of sleep in patients with lung cancer and breast cancer. J Clin Oncol 11:997-1004.
56. Smuder AJ, Kavazis AN, Min K, Powers SK. 2011. Exercise protects against doxorubicin-induced markers of autophagy signaling in skeletal muscle. J Appl Physiol 111:1190-1198.
57. Spathis A, Dhillan R, Booden D, Forbes K, Vrotsou K, Fife K. 2009. Modafinil for the treatment of fatigue in lung cancer: a pilot study. Palliat Med 23:325-331.
58. Swenson KK, Nissen MJ, Henly SJ. 2010. Physical activity in women receiving chemotherapy for breast cancer: adherence to a walking intervention. Oncol Nurs Forum 37:321-330.
59. Tisdale MJ. 2002. Cachexia in cancer patients. Nat Rev Cancer 2:862-871.
60. Tisdale MJ. 2003. Pathogenesis of cancer cachexia. J Support Oncol 1:159-168.
61. Vestergaard S, Nayfield SG, Patel KV, Eldadah B, Cesari M, Ferrucci L, Ceresini G, Guralnik JM. 2009. Fatigue in a representative population of older persons and its association with functional impairment, functional limitation, and disability. J Gerontol A Biol Sci Med Sci 64:76-82.
62. Wood LJ, Nail LM, Perrin NA, Elsea CR, Fischer A, Druker BJ. 2006. The cancer chemotherapy drug etoposide (VP16) induces proinflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy-related symptoms. Biol Res Nurs 8:157-169.
63. Young JW, Kooistra K, Geyer MA. 2011. Dopamine receptor mediation of the exploratory-hyperactivity effects of modafinil. Neuropsychopharmacology 36:1385-1396.
64. Zombeck JA, Deyoung EK, Brzezinska WJ, Rhodes JS. 2011. Selective breeding for increased home cage physical activity in collaborative cross and Hsd:ICR mice. Behav Genet 41:571-582.